Introduction
Hypoxia inducible factor (HIF) belongs to a family of transcription factors that regulate genes involved in angiogenesis, glucose metabolism and proliferation (Harris, 2002; Semenza, 2003; Ba´rdos and Ashcroft, 2005) . HIF-1, the best known member of the family, consists of HIF-1a and HIF-1b. HIF-1a protein stability and synthesis is regulated by changes in cellular oxygen concentration, pH, growth factors, oncogenes and loss of tumour suppressors (Harris, 2002; Ba´rdos and Ashcroft, 2005) . Under normoxic conditions, HIF-1a is rapidly degraded by the proteasome, which depends on the binding and targeted ubiquitination by the von Hippel-Lindau protein (pVHL) E3 ligase. Binding of pVHL to HIF-1a requires the hydroxylation of specific conserved proline residues within the oxygen-dependent degradation domain of HIF-1a and is mediated by the proline hydroxylase domain enzymes (PHD), which require oxygen, iron and 2-oxogluterate for this process (Semenza, 2001; Maxwell and Ratcliffe, 2002; Berra et al., 2003) . In hypoxia, HIF-1a protein is rapidly stabilised by the inhibition of the PHDs and translocates to the nucleus, where it binds to HIF-1b to form the HIF-1 complex, which is essential for DNA-binding and HIF-1 transactivation activity. The HIF-1 complex binds to the hypoxia response element (HRE) within target genes and recruits a number of co-activators, such as p300/CBP, Ref-1, Jab1, SCR-1 and TIF2. HIF-1 activates the expression of at least 70 genes involved in vascularization (e.g., vascular endothelial growth factor (VEGF), erythropoietin), metabolic adaptation (e.g., glucose transporters, glycolytic enzymes) and cell survival (e.g., insulin-like growth factor-1, -2, insulin) (Semenza, 2003; Ba´rdos and Ashcroft, 2005) . In addition to hypoxia, HIF-1a protein synthesis is regulated by growth factors and oncogenes (Laughner et al., 2001; Fukuda et al., 2002; Bardos and Ashcroft, 2004; Ba´rdos et al., 2004) .
Multiple signalling pathways including the Ras/Raf/ ERK1/2 cascade have been shown to play a role in regulating HIF-1 activity and upregulating VEGF expression (Minet et al., 2000; Blancher et al., 2001; Hur et al., 2001; Sodhi et al., 2001; Fukuda et al., 2002; Lee et al., 2002; Mottet et al., 2002) . Constitutive activation of the Ras/Raf/ERK1/2 pathway leads to the transformation of mammalian cells, and enhanced activity of this pathway occurs in many human cancers (Garnett and Marais, 2004; Wallace et al., 2005) . Activation of the Ras/Raf/ERK1/2 pathway may also control tumour growth by regulating HIF-1-mediated angiogenesis and glucose metabolism. In particular, ERK1 and ERK2, which are members of the mitogen-activated protein kinase (MAPK) family are thought to be involved in HIF-1 regulation (Ba´rdos and Ashcroft, 2005) . ERK1/2 has been shown to phosphorylate HIF-1a in vitro (Richard et al., 1999; Sodhi et al., 2001) , whereas it has also been reported that ERK1/2 indirectly enhances HIF-1 activity by phosphorylating p300/CBP and increasing its ability to bind to HIF-1a (Sang et al., 2003) . Previous studies have shown that the MEK1/2 inhibitor PD98059 or expression of dominant-negative (DN) forms of Ras, Raf or ERK1/2 all block HIF-1 activity to some degree in multiple cell types (Minet et al., 2000; Sodhi et al., 2001; Lee et al., 2002; Mottet et al., 2002) . However, whether selective inhibition of ERK1/2 signalling blocks HIF-1 activity or whether ERK1/2 activation itself is essential for the induction of HIF-1a and activation of HIF-1 by hypoxia and growth factors is unclear.
In this study, we show that overexpression of wildtype (WT) ERK1 greatly enhances HIF-1 activity in response to hypoxia without affecting HIF-1a expression. It also significantly increases HIF-1a induced in response to IGF-1. Surprisingly however, using the highly selective MEK1/2 inhibitor PD184325, we show for the first time that inhibition of ERK1/2 signalling blocks IGF-1-mediated induction of HIF-1a and HIF activity but does not affect HIF-1a induction or HIF-1 activation in response to hypoxia. Our study indicates that kinases other than MEK1/2 are required for HIF-1 activation in response hypoxia.
Results

ERK1/2 enhances HIF-1 activity in hypoxia
The ERK1/2 signalling pathway has been shown to play a role in the regulation of HIF-1 (Richard et al., 1999; Minet et al., 2000; Hur et al., 2001; Sodhi et al., 2001; Mottet et al., 2002; Mazure et al., 2003; Sang et al., 2003; Ba´rdos and Ashcroft, 2005) . However, it is unclear whether ERK1/2 activity is required for the induction of HIF-1a protein and activation of HIF-1 in response to hypoxia and/or growth factors. To address this, we first assessed the effects of ERK1/2 on HIF-1 activity in normoxia and hypoxia. U2OS cells stably expressing either the luciferase reporter construct pGL-HREluc (U2OS-HRE-luc) or the pGL3 luciferase control construct (U2OS-luc control) were used. These cell lines have been described previously (Chau et al., 2005) . We found that transient overexpression of WT ERK1 clearly enhanced luciferase activity in U2OS-HREluc cells (Figure 1a ) without affecting HIF-1a protein levels induced in response to both hypoxia and the hypoxia mimetic agent, deferoxamine mesylate (DFX) (Figure 1b and data not shown). We found that exogenous expression of a DN form of ERK1 reduced luciferase activity in response to hypoxia and DFX by at least 20-50% in the U2OS-HRE-luc cells ( Figure 1a and data not shown). This was not a nonspecific effect on luciferase, as expression of either WT ERK1 or DN ERK1 did not affect constitutive luciferase activity in the U2OS-luc control cells (Figure 1c and d) . The DN ERK1 construct contains alanine substitutions at key regulatory phosphorylation sites (T192 and Y194 to alanine and phenylalanine, respectively), which prevents activation of ERK1/2 and sequesters MEK1/2 (Pages et al., 1993) . DN ERK1 inhibits both ERK1 and ERK2 activity (Pages et al., 1993) . Both WT ERK1 and DN ERK1 had no significant effect on HIF-1a protein induced in response to hypoxia or DFX in U2OS or MCF-7 cells (Figure 1b and d, and data not shown), nor did they affect the electromobility of HIF-1a protein.
Inhibition of ERK1/2 activity does not affect HIF-1a induction, localization or binding to HIF-1b in response to hypoxic stress To further address the role of ERK1/2 in HIF-1 regulation, the MEK1/2 inhibitors PD98059 and PD184352 were used. U2OS-HRE-luc or MCF-7 cells were treated with or without PD98059 or PD184352 30 min before treatment with hypoxia or DFX. Basal ERK1/2 phosphorylation levels were readily detectable in the cells. PD98059 inhibited ERK1/2 phosphorylation when compared with untreated control U2OS-HRE-luc cells ( Figure 2a ) and in MCF-7 cells (Figure 2b ). Furthermore, PD184352 inhibited ERK1/ 2 phosphorylation to near undetectable levels under all conditions ( Figure 2 ). Both PD98059 and PD184352 were found to have minimal effects on HIF-1a protein levels induced in response to hypoxia or DFX in all cell lines tested (Figure 2 ) or in renal carcinoma cells that express constitutively high basal levels of HIF-1a and VEGF ( Figure 2c ; Maxwell et al., 1999; Blancher et al., 2000) . In addition, there was no significant effect of the inhibitors on the formation of the 116 kDa higher molecular weight form of HIF-1a protein (Figure 2 ) which we found to be a hyper-phosphorylated form of the protein (data not shown), consistent with previous studies (Suzuki et al., 2001) . The ERK1/2 pathway therefore is not involved in the accumulation of the HIF-1a protein in response to hypoxic stress. It is worth noting that higher concentrations of PD98059 (>50 mM) have been shown to affect HIF-1a protein levels in hypoxia (Blancher et al., 2001; Hur et al., 2001; Sang et al., 2003) , and this is most likely due to the inhibition of other MAPKs (Squires et al., 2002) . Furthermore, we showed that inhibition of ERK1/2 activity by PD98059 or PD184352 did not affect HIF-1a localization to the nucleus in response to DFX treatment ( Figure 3a ) or affect the ability of HIF-1a to bind to HIF-1b in co-immunoprecipitation assays ( Figure 3b ). Taken together, our data suggest that ERK1/2 activity is not required for the accumulation, localisation or binding of HIF-1a to HIF-1b in response to hypoxic stress (Figures 2 and 3) or for constitutive HIF-1a expression in renal carcinoma cells, which have lost pVHL function ( Figure 2c ).
Selective inhibition of MEK1/2 by PD184352 does not inhibit HIF activity in response to hypoxic stress HIF-1 activity is regulated by the transactivation domains within the C-terminal end of the HIF-1a protein (Richard et al., 1999; Lee et al., 2002) . To establish whether the ERK1/2 pathway is required for the transactivation of the HIF-1 complex in response to hypoxic stress, MCF-7 cells were transiently transfected with pGL-HRE. This construct contains a triple HRE Figure 2 Effect of PD98059 and PD184352 on HIF-1a expression in response to hypoxic stress. (a) MCF-7 or (b) U2OS-HRE-luc cells were exposed to normoxia, hypoxia (1%O 2 ), or DFX (500 mM) for 16 h in the presence or absence of the MEK1/2 inhibitor PD98059 (50 mM) or PD184352 (2 mM). Western blot analysis shows HIF-1a, phosphorylated ERK1/2 (ERK-P), or total ERK1/2 proteins. Actin was used as a load control. (c) Effect of PD98059 and PD184352 on constitutive HIF-1a expression. RCC4 cells were treated as described in Figure 7b . Western blot analysis shows HIF1a, phosphorylated ERK1/2 (ERK-P), and total ERK1/2 proteins. Actin was used as a load control.
repeat fused to the luciferase gene (Ba´rdos et al., 2004; Chau et al., 2005) . Twenty-four hours after transfection, the cells were treated with either PD98059 or PD184352 30 min before hypoxia or DFX treatment. Alternatively, U2OS-HRE-luc or U2OS-luc control cells were used (Chau et al., 2005) . Hypoxia induced a two to three fold increase in luciferase activity in MCF-7 cells when compared with normoxia ( Figure 4a ) whereas DFX induced a 20-to 35-fold increase in luciferase activity ( Figure 4a ). The difference between hypoxia and DFXinduced luciferase activity was most probably due to the respective levels of HIF-1a protein, as shown in the corresponding Western analysis (Figure 2a) . PD98059 had no effect on luciferase activity under normoxic conditions ( Figure 4 ) and did not significantly affect constitutive luciferase activity in U2OS-luc control cells (Figure 4c ), but blocked both hypoxia and DFX induced luciferase activity by approximately 50% (Figure 4a and b) . Surprisingly however, the more potent and selective MEK1/2 inhibitor PD184352 had no significant effect on luciferase reporter activity induced by hypoxia or DFX in either MCF-7 cells transiently expressing the luciferase reporter pGL-HRE (Figure 4a ) or in U20S-HRE-luc cells and U20S-luc control cells (Figure 4b and c) . However, the concentration of PD184352 used was clearly effective at inhibiting ERK1/2 phosphorylation to near non-detectable levels (Figure 2a and b) . Furthermore, luciferase activity was not inhibited, even when PD184352 was used over a concentration range ( Figure 5 ). We next wanted to assess whether PD184352 affected VEGF induced in response to hypoxia. MCF-7 cells were treated with PD98059 or PD184352 in normoxia or hypoxia, and VEGF was measured in the culture media using a sensitive enzyme-linked immunosorbent assay (ELISA) (Figure 5c ). We found that PD184352 did not block VEGF induced in response to hypoxia, whereas ERK1/ 2 phosphorylation was significantly inhibited. Interestingly, a previous study has shown that ERK5 is phosphorylated by epidermal growth factor and hydrogen peroxide in cells treated with low concentrations of PD184352 (Mody et al., 2001) . The mobility of ERK5 changes dramatically upon activation (Mody et al., 2001 ) and can be assessed by Western blot. We found that ERK5 status did not change in MCF-7 cells in response to hypoxia or in response to PD184352 treatment. In addition, we found that although exogenously expressed ERK5 could be activated by coexpression of a constitutively active form of MEK5 (MEK5D), ERK5 status was not affected by either hypoxia or PD184352 treatment (Figure 5d-f) . The discovery that PD184352 did not inhibit HIF-1 activity in response to hypoxic stress suggests the possibility that there are other kinases that regulate HIF-1 activity that are targeted by PD98059, but unaffected by the more potent and selective MEK1/2 inhibitor PD184352 (Squires et al., 2002; Dokladda et al., 2005) . PD98059 and U0126 had similar effects ( Figure 6 ) and have been used extensively to assess the effect of ERK1/2 signalling on many cellular processes. Although we have shown that overexpression of WT ERK1 can augment HIF-1 activity in hypoxia, the use of PD184352 shows for the first time that ERK1/2 signalling is not required for HIF-1a induction or HIF-1 activation in hypoxia.
DN ERK1, PD98059, U0126 and PD184352 block HIF-1a induction in response to IGF-1 In addition to cellular oxygen, HIF-1 is also induced by growth factors (Laughner et al., 2001; Ba´rdos et al., 2004 ; Figure 7a ). Recent studies using PD98059 have indicated a role for ERK1/2 signalling in the induction of HIF-1a in response to heregulin and IGF-1 over 24 h (Fukuda et al., 2002) . We found that transient expression of WT ERK1 in MCF-7 cells greatly increased HIF-1a expression in response to IGF-1 (Figure 7b) . Conversely, transient expression of DN ERK1 in MCF-7 cells blocked HIF-1a induced by IGF-1 (Figure 7a ). This was in contrast to our observations in hypoxia where neither WT ERK1 nor DN ERK1 had any effect on HIF-1a protein induction (Figure 2b and d) . Consistent with these data and confirming previous studies (Fukuda et al., 2002) , treatment of MCF-7 cells with PD98059 before stimulation with IGF-1 also blocked HIF-1 activity (Figure 7c ). In addition, treatment of these cells with U0126 or PD184352 also blocked HIF-1a induction ( Figure 7d ) and HIF-1 activity in response to IGF-1 (Figure 7c ). As we have shown PD184352 can block HIF-1a induced by IGF-1, but does not affect HIF-1a protein or activity induced by hypoxia and this suggests a clear stimulus-dependent requirement for ERK1/2 signalling in the regulation of the HIF pathway. Interestingly, we found that although PD98059 and PD184352 affected HIF-a protein levels induced by IGF-1 (Figure 7d) , this was not due to an effect on HIF-a mRNA (Figure 8a ). IGF-1 has been shown to increase HIF-1a protein synthesis (Fukuda et al., 2002; Ba´rdos et al., 2004) . In addition, MAPKs are involved in the activation of the translation machinery by activating MNK1 and MNK2 (Ueda et al., 2004) . This results in the phosphorylation and activation of the 5 0 mRNA cap-binding protein eIF-4E, which allows for the translation of proteins. To establish whether the Figure 4 Effect of PD98059 and PD184352 on HIF-1 activity. (a) MCF-7 cells were transiently co-transfected with 5 mg of the pGL3-HRE luciferase reporter construct or vector control (À) with 50 ng pCMVb-gal then exposed to normoxia, hypoxia (1% O 2 ) or DFX (500 mM) for 16 h in the presence or absence of PD98059 (50 mM), or PD184352 (2 mM) or DMSO. (b) U2OS-HRE-luc or (c) U2OS-luc control cells were treated as for (a). Graphs show luciferase reporter activity as a fold relative to untreated (normoxia) control. b-Galactosidase was used to normalise luciferase activity. Experiments were repeated at least three times in duplicate, and performed in parallel with the experiments described in Figure 2 .
Role of ERK1/2 in HIF-1 regulation KM Sutton et al ERK1/2 signalling was inhibiting HIF-1a induction by affecting eIF-4E phosphorylation, MCF-7 cells were stimulated with IGF-1 in the presence or absence of either PD98059 or PD184352. Both PD98059 and PD184352 significantly blocked elF-4E phosphorylation in response to IGF-1 treatment (Figure 8b ), indicating that HIF-1a protein levels induced by IGF-1 were affected by inhibition of the translation machinery. Finally, we found that neither PD98059 nor PD184352 could affect HIF-1a protein induced in normoxia either by treatment of MCF-7 cells with the proteasome inhibitor MG132 (data not shown) or by loss of pVHL function (Figure 2c ).
Our data suggest that mechanisms, which increase HIF-1a expression due to increased stability in normoxia and hypoxia, can be ERK1/2 signalling independent.
Discussion
The ability to survive under hypoxic conditions is one of the fundamental physiological differences between tumour and normal cells. Hypoxia is believed to act as a selective pressure leading to an aggressive tumour phenotype (Hockel and Carroll and Ashcroft, 2005) . Furthermore, a reduction in oxygen tension confers resistance to both radiotherapy and chemotherapy and in many cases correlates with a poor patient prognosis (Teicher, 1994; Semenza, 2003; Carroll and Ashcroft, 2005) . HIF-1 is central to the hypoxic response in cells, and HIF-1a is overexpressed in more than 70% of human cancers and their metastases, including bladder, breast, colon and prostate cancer (Zhong et al., 1999; . Following transfection, cells were serum starved then stimulated with or without IGF-1 (50 ng/ml) for 16 h. Western blots show HIF-1a, WT ERK1 (HA-tagged) and DN ERK1 (HAtagged) and total ERK1/2 proteins. GFP was used as a transfection control and actin was used as a load control. (b) MCF-7 cells were serum starved, then stimulated with or without IGF-1 (50 ng/ml) for the times indicated. (c) MCF-7 cells were transiently co-transfected with 5 mg of the pGL3-HRE luciferase reporter construct and 50 ng pCMV b-gal and then serum starved and exposed to normoxia alone (untreated) or treated with IGF-1 (50ng/ml) in normoxia for 16 h in the presence or absence of PD98059 (50 mM), or PD184352 (2 mM) or DMSO. (d) MCF-7 cells were serum -starved, then stimulated with or without IGF-1 (50 ng/ml) or DFX (500 mM) in the presence or absence of PD98059 (50 mM), PD184352 (2 mM), or U0126 (5 mM) for 16 h. Western blots show HIF-1a, phosphorylated ERK1/2 (ERK-P), and total ERK1/2 proteins. Actin was used as a load control.
pathway is regulated on many levels and is sensitive to multiple stimuli (Harris, 2002; Ba´rdos and Ashcroft, 2005) . In particular, the Ras/Raf/ERK1/2 pathway has previously been shown to play a role in regulating HIF-1 activity in response to both hypoxia and growth factors (Ba´rdos et al., 2004; Ba´rdos and Ashcroft, 2005) . Specifically, ERK1/2 activity has been shown to regulate HIF-1 activity in response to hypoxia using the MEK1/2 inhibitor PD98059 (Richard et al., 1999; Minet et al., 2000; Hur et al., 2001; Sodhi et al., 2001; Fukuda et al., 2002; Lee et al., 2002) or a DN form of ERK1 or ERK2 (Minet et al., 2000; Hur et al., 2001) . Consistent with these studies, we show here that PD98059 and DN ERK1 block HIF-1 activity in response to hypoxia, but do not affect HIF-1a stability. In addition, we found that BAY439006 could also significantly block HIF-1 activity in response to hypoxia (data not shown). Interestingly, we showed that PD98059 does not block HIF-1 activity by affecting HIF-1a localization or the ability for HIF-1a to bind to HIF-b. Although our observations support a role for ERK1/2 signalling in HIF-1 activation, it is not clear whether ERK1/2 activity is required for HIF-1 activation. In fact, we showed that unlike PD98059 or DN ERK1, which can inhibit other MAPKs (Squires et al., 2002; Dokladda et al., 2005) , the potent and selective MEK1/2 inhibitor PD184352 (Squires et al., 2002; Allen et al., 2003) did not inhibit HIF-1 activity induced by hypoxia. It is worth noting that while we were carrying out this study we found that obtaining significant inhibition of ERK1/2 signalling by siRNA to either MEK1/2 or ERK1/2 was challenging, highlighting the need for the availability of selective inhibitors of this pathway for research purposes. Taken together, our study suggests that ERK1/2 signalling is not required for either the induction of HIF-1a protein or HIF-1 activity in hypoxia.
In addition to hypoxia, HIF-1a is also induced by growth factors such as IGF-1 (Fukuda et al., 2002; Ba´rdos et al., 2004) . It is clear from our studies that transient overexpression of WT ERK1 can augment the HIF-1 response to both hypoxia and IGF-1. Although our observations suggest that ERK1/2 activity is not required for the former, we show that PD184352 completely blocks HIF-1a induction and elF-4E phosphorylation in response to IGF-1, suggesting that ERK1/2 signalling is important for the latter and that ERK1/2 signalling can potentially cooperate with other pathways to drive HIF-1 activity in hypoxia (Michiels et al., 2001) .
The finding that selective MEK1/2 inhibitors such as PD184352 do not affect HIF-1a stabilized in normoxia or hypoxia, but do block IGF-1-induced expression indicates a clear mechanistic difference in how stimulus and cell type can affect the relative contribution of ERK1/2 signalling to the HIF response in tumour cells.
Materials and methods
Antibodies and plasmids
A monoclonal antibody to HIF-1a was purchased from BD Bioscience (Oxford, UK). Polyclonal phospho-specific p42/ p44, phospho-specific eIF-4E and total eIF-4E were purchased from Cell Signalling Technology (MA, USA). The polyclonal total ERK1/2 antibody was purchased from Santa Cruz Biotechnology (CA, USA). The monoclonal actin antibody was purchased from Abcam (Cambridge, UK) and the monoclonal GFP antibody was purchased from Clontech Laboratories (Saint-Germain-en-Laye, France). Anti-mouse and anti-rabbit secondary antibodies were purchased from Amersham Biosciences (Cardiff, UK). Primary and secondary antibodies were used at 1 in 1000 dilution in 0.1% (v/v) Tween-20/Tris buffered saline (TBS-T) containing 5% (w/v) powdered milk. The secondary antibody for immunostaining (Alexa Fluro-488 goat anti-mouse IgG1) was purchased from Molecular Probes (Leiden, The Netherlands). The full-length human HIF-1a expression construct (pCMVb-HA-HIF-1a) was kindly provided by Andrew Kung (Dana-Farber Cancer Institute, Boston, MA,VSA). Plasmids encoding WT ERK1 and DN ERK1 have been described previously (Pages et al., 1993) . Plasmids encoding flag-ERK5 and HA-MEK5D were kind gifts from Dr Simon Cook (The Babraham Institute Effect of ERK1/2 signalling on HIF-1a mRNA expression in response to IGF-1. MCF-7 cells were treated as described in Figure 7c . RNA was then extracted from cell lysates and subjected to quantitative PCR analysis. (a) Graph shows the mean HIF-1a mRNA levels from duplicate samples. Actin was used to normalize mRNA values. Experiments were repeated at least three times. (b) MCF-7 cells were treated in parallel with the experiments described in Figure 7c Western blot analysis shows phosphorylated elF-4E and total elF-4E proteins. Actin was used as a load control.
Cambridge, UK). The pGL-HRE-luc and pCMV-b-gal have been used previously (Ba´rdos et al., 2004; Chau et al., 2005) .
Cell culture
The human breast adenocarcinoma cell line MCF-7 was purchased from the American Type Culture Collection. The RCC4 cells were a kind gift from Professor Patrick Maxwell (Imperial College, London, UK) and have been described previously (Maxwell et al., 1999) . The U2OS-HRE-luc and USOS-luc control cells have been described previously (Chau et al., 2005) . All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco-BRL), containing 10% foetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 mg), and L-glutamine (2 mM). All cells lines were incubated at 371C in a non-humidified incubator with 95% air and 5% carbon dioxide (CO 2 ).
Inductions and drug treatments Physiological hypoxia was achieved by incubating cells at 1% oxygen, 5% CO 2 and 94% nitrogen in a LEEC dual gas incubator (GA-156). HEPES of 20 mM (Gibco, Scotland, UK) was added to all cells before incubation under hypoxic conditions. The hypoxic mimetic agent, DFX, was used at a final concentration of 500 mM. For treatment with IGF-1, cells were starved for 36-48 h and then stimulated with 50 ng/ml of recombinant IGF-1 (Sigma, MO, USA) for the desired time. The MEK1/2 inhibitors PD98059 (Cell Signalling Technologies, MA, USA), PD184352, and U0126 (Promega Biosciences, CA, USA) were dissolved in dimethyl sulfoxide (DMSO), and used at 50, 2 and 5 mM respectively, unless otherwise stated. PD98059, PD184352, or U0126 were added to cells 30 min before hypoxia (1% O 2 ), DFX (500 mM) or IGF-1 (50 ng/ml) treatments. Transient transfections were carried out using the calcium phosphate precipitation method, and cells were harvested either in NP-40 lysis buffer (100 mM Tris (pH 8.0), 100 mM NaCl 2 , 1% NP-40) containing a protease inhibitor cocktail (ethylene diaminetetraacetic acid (EDTA) free; Boehringer Mannheim) or in 2 Â sample buffer (125 mM Tris (pH 6.8), 4% sodium dodecyl sulfate (SDS), 0.01% bromophenol blue, 10% b-mercaptoethanol, 10% glycerol) for subsequent separation by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. For measurement of VEGF, conditioned media was removed and analysed for VEGF protein levels by ELISA (QuantiGlo, R&D Systems, Minneapolis, MN, USA), and calibration curves were performed for all experiments.
Luciferase assay
Following treatment, cells were lysed with Passive Lysis buffer (Promega Biosciences). Cell lysate 20 ml was added to each well of a 96-well plate and analysed immediately after addition of 100 ml luciferase assay system reagent (Promega Biosciences) in a Dynex luminometer (Dynex Technologies, Worthing, UK). Experiments were carried out in duplicate, unless otherwise stated. Luciferase activity was measured as relative light units and converted to fold induction relative to control. Luciferase activity was normalized to the corresponding b-galactosidase activity by transiently transfecting cells with 50 ng pCMVbgal. To assay for b-galactosidase activity, 20 ml cell lysate was added to 1 ml chlorophenol red-b-D-galactopyranoside (CPRG, Roche Diagnostics, IN, USA). Samples were incubated at 371C overnight and absorbance readings were performed at a wavelength of 595 nm using a CECIL spectrophotometer (CE2502 2000 series, Bioquest, Cambridge, UK).
Immunostaining
Cells were seeded in 24-well plates on top of sterile glass coverslips. Following treatment, cells were fixed with 4% paraformaldehyde in (1 Â phosphate-buffered saline (PBS). Cells were stained for HIF-1a using a specific monoclonal antibody as previously described (Ba´rdos et al., 2004) . The secondary antibody Alexa Fluro-488 goat anti-mouse IgG1 (Molecular Probes) was diluted in IFF 1 Â PBS containing 1% bovine serum albumin and 2% FCS. Nuclei were visualized by TOPRO-3 staining.
Quantitative PCR Total RNA was harvested from cells using the Qiagen RNeasy kit (Qiagen GmbH, Sussex, UK), following the manufacturer's instructions for the RNeasy mini protocol for isolation of total RNA from animal cells, spin protocol. Total RNA 1-5 mg was reverse transcribed to cDNA using the SuperScripit firststrand synthesis system for RT-PCR (Invitrogen, Scotland, UK) with random primers, following the manufacturer's protocol. qPCR of HIF-1a was performed using the primers: sense GCAAGCCCTGAAAGCG and antisense GGCTG TCCGACTTTGA. qPCR was carried out using the DyNAmo SYBR Green kit (Finnzymes, Finland). To each sample reaction the following was added: 200 ng cDNA, 10 ml DyNAmo SYBR Green, 0.3 mM of forward and reverse prime, and were made up to a total volume of 20 ml with PCR grade water. Samples were amplified in a continuous fluorescence detector (DNA Engine Cycler (PTC-200) Opticon 2 (CFD-3220) real-time PCR machine, MJ Research Inc. MA, USA) with the following cycling parameters: Initial denaturation of 10 min at 951C, 20 s at 941C, 20 s at 551C, 20 s at 721C for 36 cycles and 5 min at 721C. Melting curves were generated from 70 to 901C, with readings for 1 s taken every 0.21C.
